SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
Eric Karas, ARS Pharmaceuticals' Chief Commercial Officer, is named as a defendant in a securities class action alleging investors were misled about the timing of expanded CVS Caremark coverage for neffy before SPRY shares fell 23.9% in one session. NEW YORK, Sept. 10, 2026 /PRNewswire/...
Covered in this story
What has happened since
- Ars Pharmaceuticals Inc is down 14.6% since this was published, 42 days ago.
- CVS Health is down 0.9% since this was published, 42 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SPRY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ars Pharmaceuticals Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.